Literature DB >> 21857143

One-year cardiovascular event rates in Japanese outpatients with myocardial infarction, stroke, and atrial fibrillation. -Results From the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE).-.

Shinya Goto1, Yasuo Ikeda, Kazuyuki Shimada, Shinichiro Uchiyama, Hideki Origasa, Hiroyuki Kobayashi.   

Abstract

BACKGROUND: There remains uncertainty about the risk of cardiovascular events in stable outpatients with a history of myocardial infarction (MI), stroke, and atrial fibrillation in Japan. METHODS AND
RESULTS: In the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE), a nationwide prospective cohort of stable outpatients with a history of MI (n=2,291), stroke (n=3,554), and/or atrial fibrillation (n=2,242), 1-year follow-up data were available for 7,513 of 8,087 patients (follow-up rate: 92.9%). The primary endpoint (death/MI/stroke) was reported in 3.53 events per 100 person-years (95% confidence interval [CI]: 3.11-3.99) within 1 year. The rates of all-cause death, death from stroke, and death from MI within 1 year were 1.35 (95%CI: 1.10-1.65), 0.15 (95%CI: 0.08-0.27), and 0.06 (95%CI: 0.02-0.14) per 100 person-years, respectively. The rate of non-fatal stroke was 1.85 (95%CI: 1.55-2.19), while that of non-fatal MI was 0.33 (95%CI: 0.21-0.49). The rate of non-fatal stroke was highest among stroke patients (2.95; 95%CI: 2.39-3.60 per 100 person-years), while that of non-fatal MI was similar across all disease categories. Investigator-decided serious non-fatal bleeding events occurred in 0.21 events (95%CI: 0.12-0.34) per 100 person-years.
CONCLUSIONS: In this large, nationwide Japanese registry, the highest stroke event rate was seen in patients with a history of stroke.

Entities:  

Mesh:

Year:  2011        PMID: 21857143     DOI: 10.1253/circj.cj-11-0378

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  6 in total

1.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

Review 2.  Oral anticoagulants for Asian patients with atrial fibrillation.

Authors:  Ian Sabir; Kaivan Khavandi; Jack Brownrigg; A John Camm
Journal:  Nat Rev Cardiol       Date:  2014-03-11       Impact factor: 32.419

Review 3.  Safety of antithrombotic therapy in East Asian patients.

Authors:  Shinya Goto; Shinichi Goto
Journal:  Intern Emerg Med       Date:  2021-03-08       Impact factor: 3.397

Review 4.  The imminent epidemic of atrial fibrillation and its concomitant diseases - Myocardial infarction and heart failure - A cause for concern.

Authors:  Christin S Börschel; Renate B Schnabel
Journal:  Int J Cardiol       Date:  2018-11-30       Impact factor: 4.164

5.  Drug-eluting versus bare-metal stents for first myocardial infarction in patients with atrial fibrillation: A nationwide population-based cohort study.

Authors:  Nen-Chung Chang; Patrick Hu; Tien-Hsing Chen; Chun-Tai Mao; Ming-Jui Hung; Chi-Tai Yeh; Ming-Yow Hung
Journal:  PLoS One       Date:  2020-01-10       Impact factor: 3.240

Review 6.  Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms.

Authors:  Francesco Violi; Elsayed Z Soliman; Pasquale Pignatelli; Daniele Pastori
Journal:  J Am Heart Assoc       Date:  2016-05-20       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.